HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Frontier Programs conduct visionary research that translates to cutting-edge clinical care. They offer answers often not available anywhere else in the world: a breakthrough therapy that teaches a child's own cells to fight cancer, a first-of-its-kind surgery for chest deformities, a lifesaving treatment based on a new understanding of the body's lymphatic system, and more. CHOP champions these programs and ensures that they receive critical support to accelerate their progress. By investing in Frontier Programs that bring the best minds to the most challenging conditions, CHOP is once again redefining what's possible.
Advancing our translational research program to improve understanding of the pathophysiology of heart failure unique to children and those with congenital heart disease to become the international leader in discovery, prevention, and treatment of advanced heart failure in children.
Revolutionizing our understanding of the genetic causes and mechanisms of hyperinsulinism, developing diagnostic tools for a precision-medicine approach to treatment, and discovering new treatment options.
Developing and testing a new optical device that permits continuous noninvasive monitoring to accurately track cerebral blood flow and cerebral oxygen metabolism in underlying brain tissue.
Shifting the paradigm to treat the toughest pediatric cancers with new cell therapies that reprogram a patient's own immune system to kill cancer cells.
Combining extraordinary care, innovative translational research, and novel innovations to improve outcomes for children with common and complex airway disorders.
Revolutionizing the diagnosis and treatment of pediatric heart valve disease through translational and basic science, emerging technology, and advanced imaging to provide specific strategies of care individualized to each patient.
Translating treatment guidelines into structured care plans for gastrointestinal motility patients and using precision medicine to develop new therapies and treatment strategies, all with the goal of improving outcomes for children.
Providing personalized treatment strategies, using comprehensive multi-omic tumor profiling, to define the best individual treatment options. This includes clinical trials for patients who lack effective standard of care treatments, or who have relapsed or refractory cancers.
Pioneering new approaches to diagnosis, care, and treatment for patients with red blood cell disorders with novel gene therapies and stem-cell-based treatments that aim to reduce symptoms and prolong life.
Creating an expert, multidisciplinary team to provide evidence-based care for patients with complex vascular anomalies and researching the genetic basis for these cases to inform new therapeutic approaches.
Continuously building upon multidisciplinary expertise to improve care and understanding of long-term outcomes for babies born with congenital diaphragmatic hernia and developing new treatment modalities.
The Delivery Room of the Future Frontier Program applies a data-driven approach to optimize patient outcomes, improve provider performance, and innovate methods to support clinical decision-making during newborn resuscitation for infants with congenital anomalies.
Expanding access to genetic testing to all children with epilepsy and offering individualized treatment plans informed by novel genetic findings.
Conducting laboratory, translational, and clinical research to revolutionize medications and therapies aimed at eradicating childhood food allergies.
Expanding ways to rapidly evaluate immune function, identifying genetic defects underlying immune dysregulation, and accelerating new immunotherapeutics.
Generating new insights from multidisciplinary translational research to provide personalized therapy worldwide for more children with inflammatory bowel disease.
Developing advanced imaging and interventional techniques to more accurately identify and manage lymphatic leaks and lymphatic flow disorders.
Converging individualized basic, translational, and clinical research programs dedicated to improving the health of patients of all ages living with mitochondrial disease.
Advancing evidence-based treatments for infants with chronic lung disease, with a focus on translational research to establish a therapeutic approach called liquid ventilation.
Combining our proven clinical expertise in hemophilia gene therapy and care of bleeding disorders with our research expertise to solidify Children’s Hospital of Philadelphia as the premier center for the therapeutic development and advanced clinical care of inherited bleeding disorders.
Developing a deeper understanding of diseases that cause thoracic insufficiency syndrome (TIS) and pioneering new devices to provide the best care in the world for patients with TIS.